Dynamics of body composition and bone in patients with juvenile idiopathic arthritis treated with growth hormone.

What Was Tested

This clinical trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

GH has a positive impact on growth, bone, and muscle development.

Who Took Part

The abstract describes 12 patients taking part.

The age groups tagged for this paper are children, teenagers, young adults and adults, both men and women.

In this longitudinal study, parameters of bone mineral density and geometry as well as muscle and fat cross-sectional area (CSA) in the nondominant forearm were recorded using peripheral quantitative computed tomography at yearly intervals until final height in 12 patients (seven females) receiving GH treatment.

Data at final height were compared with 13 patients (nine females) with JIA not treated with GH.

What Was Measured

The subject headings attached to it are Absorptiometry, Photon, Arthritis, Juvenile, Body Composition, Body Height, Bone Density, Bone and Bones and Growth Disorders.

What This Means in Plain Language

This is a clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 12 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2010 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.